| dc.description.abstract | Insulin analogues, developed by molecular engineering, have
structural changes in the A and B insulin chains. These modifications change their action
profile, rendering insulin replacement closer to physiology. Rapid acting analogues like lispro,
aspart and glulisine, are absorbed rapidly from the subcutaneous tissue to the circulation. In
addition, two long acting insulin analogues have been developed: glargine and detemir. The
combination of a long acting insulin, to maintain baseline levels, and multiple daily doses of a
rapid acting analogue are the mainstay of basal-bolus therapy. Multiples studies have compared
human insulin (NPH and regular) with insulin analogues in patients with type 1 or 2 diabetes
mellitus, showing an improvement in the metabolic control, fewer hypoglycemic events and
better quality of life. In summary, insulin analogues offer new therapeutic options and allow an
individualized intensive treatment. | |
